United States Healthcare Equipment & Supplies

AngioDynamics Inc (ANGO)

Track

Over the past 90 days, AngioDynamics Inc. recorded one insider transaction involving a proposed sale of 23,370 shares by officer Warren Nighan, valued at approximately $344,004. This activity follows a period where the stock price increased by 34.5%. The company's most recent earnings report in July 2026 showed an EPS beat of 36.36%.
Ticker: ANGO Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for AngioDynamics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 30 Jul 2026
Value US$1,939,314.19 | Price 376.71 | Shares 649 (-7.6%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-31 2026-07-30 S Sale
3.3
Nighan Warren JR

SVP Quality and Regulatory

Officer
649 -7.6%
376.71
US$1,939,314 		649 -7.6% 376.71 US$1,939,314
2026-07-30 2026-07-30 PrS Proposed sale
3.3
WARREN NIGHAN

Officer

Officer
16,983
90.57
US$4,824,474 		16,983 90.57 US$4,824,474
2025-10-22 2025-10-21 B Purchase
0.9
Weiss Lawrence T

SVP, Chief Legal Officer

Officer
97,733 -36.5%
375.17
US$3,806,127 		97,733 -36.5% 375.17 US$3,806,127
2025-10-14 2025-10-13 B Purchase
3.2
Trowbridge Stephen A

EVP and CFO

Officer
890 +0.3%
11.16
US$9,932 		890 +0.3% 11.16 US$9,932
2025-10-09 2025-10-09 B Purchase
3.6
Clemmer James C

President and CEO

Executive Director
10,000 +1.1%
11.15
US$111,500 		10,000 +1.1% 11.15 US$111,500
2025-01-17 2025-01-16 S Sale
3.3
Nighan Warren JR

SVP Quality and Regulatory

Officer
4,060 -8.8%
12.31
US$49,979 		4,060 -8.8% 12.31 US$49,979
2025-01-16 2025-01-16 PrS Proposed sale
3.3
Nighan Warren JR

Officer

Officer
4,060
12.31
US$49,979 		4,060 12.31 US$49,979
2024-10-10 2024-10-10 B Purchase
3.3
Nighan Warren JR

SVP Quality and Regulatory

Officer
100 +0.2%
6.08
US$608 		100 +0.2% 6.08 US$608
2024-10-08 2024-10-08 B Purchase
3.2
Trowbridge Stephen A

EVP and CFO

Officer
1,700 +1.0%
5.86
US$9,962 		1,700 +1.0% 5.86 US$9,962
2024-10-10 2024-10-07 B Purchase
3.3
Nighan Warren JR

SVP Quality and Regulatory

Officer
768 +1.7%
6.09
US$4,677 		768 +1.7% 6.09 US$4,677
2024-10-08 2024-10-07 B Purchase
3.6
Clemmer James C

President and CEO

Executive Director
20,000 +3.0%
6.03
US$120,600 		20,000 +3.0% 6.03 US$120,600
2024-04-08 2024-04-08 B Purchase
3.6
Clemmer James C

President and CEO

Executive Director
10,000 +1.9%
6.70
US$67,000 		10,000 +1.9% 6.70 US$67,000
2023-02-01 2023-01-31 S Sale
3.6
Helsel Dave

SVP Global Operations and R&D

Officer
4,633 -19.4%
12.95
US$59,997 		4,633 -19.4% 12.95 US$59,997
2022-10-12 2022-10-12 B Purchase
3.2
Trowbridge Stephen A

EVP and CFO

Officer
1,083 +1.2%
13.82
US$14,967 		1,083 +1.2% 13.82 US$14,967
2022-10-11 2022-10-10 B Purchase
3.6
Clemmer James C

President and CEO

Executive Director
10,000 +2.3%
15.00
US$150,000 		10,000 +2.3% 15.00 US$150,000
2022-08-01 2022-07-29 S Sale
3.6
Helsel Dave

SVP Global Operations and R&D

Officer
5,000 -17.3%
22.44
US$112,200 		5,000 -17.3% 22.44 US$112,200
2022-05-02 2022-04-28 S Sale
3.6
Helsel Dave

SVP Global Operations and R&D

Officer
3,513 -13.3%
22.44
US$78,832 		3,513 -13.3% 22.44 US$78,832
2022-04-13 2022-04-12 S Sale
2.3
JOHNSON WESLEY
Non-Executive Director
1,299 -1.6%
23.26
US$30,215 		1,299 -1.6% 23.26 US$30,215
2022-04-13 2022-04-11 S Sale
2.3
JOHNSON WESLEY
Non-Executive Director
6,201 -7.2%
23.00
US$142,623 		6,201 -7.2% 23.00 US$142,623
2022-01-12 2022-01-12 B Purchase
3.2
Trowbridge Stephen A

EVP and CFO

Officer
1,000 +1.3%
22.64
US$22,640 		1,000 +1.3% 22.64 US$22,640
2022-01-12 2022-01-11 B Purchase
3.6
Clemmer James C

President and CEO

Executive Director
10,000 +2.6%
22.84
US$228,400 		10,000 +2.6% 22.84 US$228,400
2021-10-21 2021-10-20 S Sale
3.6
Helsel Dave

SVP Global Operations and R&D

Officer
3,494 -11.7%
27.97
US$97,727 		3,494 -11.7% 27.97 US$97,727
2021-10-18 2021-10-15 S Sale
2.4
Centea Scott

Sr. VP/GM, Global VIT

Officer
12,000 -20.6%
27.92
US$335,040 		12,000 -20.6% 27.92 US$335,040
2021-10-06 2021-10-05 S Sale
1.6
Campbell Chad Thomas

SVP/GM, Vascular Access

Officer
10,748 -25.3%
27.15
US$291,808 		10,748 -25.3% 27.15 US$291,808
2021-04-15 2021-04-14 S Sale
3.6
Helsel Dave

SVP Global Operations and R&D

Officer
3,500 -15.5%
23.93
US$83,755 		3,500 -15.5% 23.93 US$83,755
2021-01-21 2021-01-20 S Sale
2.3
JOHNSON WESLEY
Non-Executive Director
6,500 -7.7%
18.53
US$120,445 		6,500 -7.7% 18.53 US$120,445
2020-08-12 2020-08-11 B Purchase
3.2
Trowbridge Stephen A

EVP and CFO

Officer
1,013 +1.7%
9.38
US$9,502 		1,013 +1.7% 9.38 US$9,502
2020-08-03 2020-07-31 B Purchase
3.6
Clemmer James C

President and CEO

Executive Director
40,000 +13.2%
8.26
US$330,400 		40,000 +13.2% 8.26 US$330,400
2019-10-28 2019-10-25 B Purchase
3.6
Clemmer James C

President and CEO

Executive Director
15,000 +6.1%
14.19
US$212,850 		15,000 +6.1% 14.19 US$212,850
2019-07-18 2019-07-16 S Sale
3.2
Gould Kevin J
13,650 -19.8%
21.45
US$292,792 		13,650 -19.8% 21.45 US$292,792
2018-11-08 2018-11-07 S Sale Greiner Michael

EVP and CFO

Officer
1,939 -8.6%
21.53
US$41,747 		1,939 -8.6% 21.53 US$41,747
2017-11-17 2017-11-15 S Sale Richard Stark

SVP, GM - Oncology
27,409 -56.9%
16.29
US$446,493 		27,409 -56.9% 16.29 US$446,493
2017-07-25 2017-07-24 B Purchase REED JAN STERN Non-Executive Director
316 +inf%
16.00
US$5,056 		316 +inf% 16.00 US$5,056
2017-07-21 2017-07-21 B Purchase Clemmer James C

President and CEO

Executive Director
5,000 +5.8%
15.79
US$78,950 		5,000 +5.8% 15.79 US$78,950
2017-07-21 2017-07-21 B Purchase DONNELLY HOWARD W Non-Executive Director
5,000 +11.7%
15.72
US$78,600 		5,000 +11.7% 15.72 US$78,600
2017-07-21 2017-07-20 B Purchase Clemmer James C

President and CEO

Executive Director
20,000 +30.0%
15.64
US$312,800 		20,000 +30.0% 15.64 US$312,800
2017-04-14 2017-04-12 S Sale Avista Capital Partners GP, LLC Large shareholder
384,184 -50.2%
16.00
US$6,146,944 		384,184 -50.2% 16.00 US$6,146,944
2017-04-14 2017-04-12 S Sale Avista Capital Partners GP, LLC Large shareholder
508,869 -50.2%
16.00
US$8,141,904 		508,869 -50.2% 16.00 US$8,141,904
2017-04-14 2017-04-12 S Sale Avista Capital Partners GP, LLC Large shareholder
1,456,947 -50.2%
16.00
US$23,311,152 		1,456,947 -50.2% 16.00 US$23,311,152
2017-04-14 2017-04-12 S Sale Burgstahler David F Large shareholder
384,184 -50.2%
16.00
US$6,146,944 		384,184 -50.2% 16.00 US$6,146,944
2017-04-14 2017-04-12 S Sale Burgstahler David F Large shareholder
508,869 -50.2%
16.00
US$8,141,904 		508,869 -50.2% 16.00 US$8,141,904
2017-04-14 2017-04-12 S Sale Burgstahler David F Large shareholder
1,456,947 -50.2%
16.00
US$23,311,152 		1,456,947 -50.2% 16.00 US$23,311,152
2016-11-22 2016-11-18 S Sale Avista Capital Partners GP, LLC Large shareholder
541,349 -34.8%
15.68
US$8,488,352 		541,349 -34.8% 15.68 US$8,488,352
2016-11-22 2016-11-18 S Sale Burgstahler David F Non-Executive Director Large shareholder
541,349 -34.8%
15.68
US$8,488,352 		541,349 -34.8% 15.68 US$8,488,352
2016-11-22 2016-11-18 S Sale Avista Capital Partners GP, LLC Large shareholder
1,549,945 -34.8%
15.68
US$24,303,138 		1,549,945 -34.8% 15.68 US$24,303,138
2016-11-22 2016-11-18 S Sale Burgstahler David F Non-Executive Director Large shareholder
1,549,945 -34.8%
15.68
US$24,303,138 		1,549,945 -34.8% 15.68 US$24,303,138
2016-08-05 2016-08-05 S Sale Burgstahler David F Non-Executive Director Large shareholder
487,214 -23.9%
14.62
US$7,123,069 		487,214 -23.9% 14.62 US$7,123,069
2016-08-05 2016-08-05 S Sale Burgstahler David F Non-Executive Director Large shareholder
367,836 -23.9%
14.62
US$5,377,762 		367,836 -23.9% 14.62 US$5,377,762
2016-08-05 2016-08-05 S Sale Avista Capital Partners GP, LLC Large shareholder
478,214 -23.5%
14.62
US$6,991,489 		478,214 -23.5% 14.62 US$6,991,489
2016-08-05 2016-08-05 S Sale Avista Capital Partners GP, LLC Large shareholder
367,836 -23.9%
14.62
US$5,377,762 		367,836 -23.9% 14.62 US$5,377,762
2016-08-05 2016-08-05 S Sale Burgstahler David F Non-Executive Director Large shareholder
1,394,950 -23.9%
14.62
US$20,394,169 		1,394,950 -23.9% 14.62 US$20,394,169
2016-08-05 2016-08-05 S Sale Avista Capital Partners GP, LLC Large shareholder
1,394,950 -23.9%
14.62
US$20,394,169 		1,394,950 -23.9% 14.62 US$20,394,169
2016-05-09 2016-05-06 S Sale Greiner Charles R

VP - Global Franchise

Officer
3,508 -14.4%
12.31
US$43,183 		3,508 -14.4% 12.31 US$43,183
2016-04-25 2016-04-25 S Sale Trowbridge Stephen A

SVP and General Counsel

Officer
2,440 -7.5%
12.18
US$29,719 		2,440 -7.5% 12.18 US$29,719
2016-04-25 2016-04-21 S Sale Trowbridge Stephen A

SVP and General Counsel

Officer
10,500 -24.4%
12.33
US$129,465 		10,500 -24.4% 12.33 US$129,465
2015-02-19 2015-02-13 S Sale Richard Stark

SVP, GM - Oncology

Officer
18,100 -38.7%
18.53
US$335,393 		18,100 -38.7% 18.53 US$335,393
2014-10-21 2014-10-20 S Sale Greiner Charles R

VP - Global Franchise

Officer
3,298 -13.0%
15.63
US$51,548 		3,298 -13.0% 15.63 US$51,548
2013-11-15 2013-11-14 S Sale Greiner Charles R

VP - Global Finance

Officer
4,373 -15.9%
15.46
US$67,611 		4,373 -15.9% 15.46 US$67,611
2013-11-15 2013-11-13 S Sale Greiner Charles R

VP - Global Finance

Officer
2,392 -9.4%
15.40
US$36,842 		2,392 -9.4% 15.40 US$36,842
2013-10-21 2013-10-18 B Purchase BUCCI VINCENT Non-Executive Director
5,000 +6.1%
15.20
US$75,990 		5,000 +6.1% 15.20 US$75,990
2013-10-21 2013-10-17 S Sale DONNELLY HOWARD W Non-Executive Director
20,000 -55.8%
15.06
US$301,200 		20,000 -55.8% 15.06 US$301,200
2013-07-23 2013-07-22 B Purchase Gould Kevin J Non-Executive Director
2,700 +32.7%
12.00
US$32,400 		2,700 +32.7% 12.00 US$32,400
2013-03-13 2013-03-12 B Purchase BUCCI VINCENT Non-Executive Director
10,000 +333.3%
10.80
US$108,000 		10,000 +333.3% 10.80 US$108,000
2013-03-13 2013-03-12 B Purchase BUCCI VINCENT Non-Executive Director
35,000 +1166.7%
10.76
US$376,600 		35,000 +1166.7% 10.76 US$376,600
2013-03-13 2013-03-12 B Purchase BUCCI VINCENT Non-Executive Director
40,000 +103.4%
10.78
US$431,200 		40,000 +103.4% 10.78 US$431,200
2013-03-12 2013-03-12 B Purchase Meteny Dennis S Non-Executive Director
4,600 +26.5%
10.82
US$49,772 		4,600 +26.5% 10.82 US$49,772
2013-02-15 2013-02-14 B Purchase BUCCI VINCENT Non-Executive Director
2,000 +5.5%
12.17
US$24,332 		2,000 +5.5% 12.17 US$24,332
2013-01-14 2013-01-11 B Purchase Gould Kevin J Non-Executive Director
2,700 +48.6%
11.58
US$31,277 		2,700 +48.6% 11.58 US$31,277
2012-11-13 2012-11-05 B Purchase GOLD JEFFREY Non-Executive Director
1,000 +4.1%
10.56
US$10,560 		1,000 +4.1% 10.56 US$10,560
2012-11-09 2012-11-05 S Sale Richard Stark

SVP, GM - Oncology

Officer
3,160 -10.9%
10.36
US$32,738 		3,160 -10.9% 10.36 US$32,738
2012-07-18 2012-07-17 B Purchase DEVIVO JOSEPH

President and CEO

Executive Director
2,000 +5.6%
11.67
US$23,340 		2,000 +5.6% 11.67 US$23,340
2012-05-17 2012-05-16 S Sale Richard Stark

SVP, GM - Oncology

Officer
2,080 -9.0%
12.42
US$25,827 		2,080 -9.0% 12.42 US$25,827
2012-04-13 2012-04-12 B Purchase BUCCI VINCENT Non-Executive Director
4,000 +inf%
11.82
US$47,280 		4,000 +inf% 11.82 US$47,280
2012-04-12 2012-04-11 B Purchase Gould Kevin J Non-Executive Director
2,700 +inf%
11.72
US$31,636 		2,700 +inf% 11.72 US$31,636
2012-04-10 2012-04-10 B Purchase Kapusta Matthew C

SVP, Business Development

Officer
1,000 +6.7%
11.40
US$11,397 		1,000 +6.7% 11.40 US$11,397
Explore more

More insider trading research around AngioDynamics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Healthcare Services companies with insider activity
More Healthcare Equipment & Supplies companies with insider activity
Insider trading in North America